Vetter, a German contract development and manufacturing organisation (CDMO), has unveiled plans to invest €300m for expanding and upgrading its manufacturing facilities over a five year period.

The firm started the first of its facility expansions at various locations in Germany, including its Ravensburg Vetter West centre for visual inspection and logistics, in order to prepare them for future requirements.

According to the company, the upgrades are being driven by a changing healthcare market that is affected by issues such as complex molecules, smaller batch sizes, and increasing regulatory requirements.

Vetter completed structural work for the facility expansion, which will double the plant’s existing capacity. The site is expected to begin operations in 2017.

The plans also include expansion of the Ravensburg Vetter South production site and the Ravensburg Schuetzenstrasse facility.

The site expansion will increase drug product manufacturing capabilities and offer additional logistic services.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We are continuously monitoring and reacting to a changing marketplace and are pleased that we are in the position to be able to make these strategic investments."

Vetter will implement an in-house made enhanced restricted access barrier system (RABS) concept for increased operational excellence in aseptic manufacturing.

All planned activities are designed to meet future customer expectations and regulatory requirements at an early stage.

Vetter managing director Peter Soelkner said: "We are continuously monitoring and reacting to a changing marketplace and are pleased that we are in the position to be able to make these strategic investments to further develop our sites and meet these challenges.

"Individually and collectively, they will help us keep pace with the market and allow us to continue to build a successful future for Vetter and our customers."

In January, the company completed the first phase of a multi-functional building at its Ravensburg Schuetzenstrasse site.

The new facility, which is scheduled to be fully operational by the beginning of 2016, will feature high-tech laboratories and workplaces for Vetter’s development service, as well as a secure data centre and further office space with a total area of 8,500m².

Vetter is a contract manufacturer and specialises in the production of aseptically prefilled syringe systems, cartridges and vials.

Image: A portion of the €300m investment will be used to complete the Ravensburg Vetter West facility expansion. Photo: courtesy of Vetter.